| Cheng, Xiangdong |
NCT03973008: Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 408 | RoW | Adjuvant Chemoradiotherapy, CRT, Adjuvant Chemotherapy, CT | Zhejiang Cancer Hospital | Gastric Adenocarcinoma | 02/24 | 05/25 | | |
NCT04135781: Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer |
|
|
| Recruiting | 3 | 616 | RoW | nab paclitaxel, albumin bound paclitaxel, Tegafur, S-1, Oxaliplatin, Capecitabine | Zhejiang Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Stomach Cancer | 10/24 | 10/24 | | |
| Active, not recruiting | 2/3 | 580 | RoW | Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin, Apatinib 500mg | Ruijin Hospital | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | 12/24 | 08/25 | | |
NCT05009953: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer |
|
|
| Terminated | 2 | 17 | RoW | Irinotecan Liposome Injection, SG001, Fluorouracil, Leucovorin | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma | 01/23 | 01/23 | | |
| Not yet recruiting | 2 | 134 | RoW | Tislelizumab, SOX/XELOX | Xiangdong Cheng, Liaoning Tumor Hospital & Institute, Shanxi Province Cancer Hospital, Sichuan Cancer Hospital and Research Institute, The Second Affiliated Hospital of Harbin Medical University | Gastric Cancer | 03/26 | 03/28 | | |
| Not yet recruiting | 2 | 50 | RoW | Liposomal Irinotecan Hydrochloride | Zhejiang Cancer Hospital | Gastric Cancer | 02/25 | 02/26 | | |
NCT05864105: PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 35 | RoW | PM8002, FOLFOX regimen | Biotheus Inc. | Hepatocellular Carcinoma | 06/26 | 06/26 | | |
NCT06586294: A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma |
|
|
| Not yet recruiting | 1/2 | 294 | RoW | Drug: AK129 Drug：oxaliplatin Drug：capecitabine, Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 07/26 | 07/26 | | |
| Not yet recruiting | 1/2 | 54 | RoW | QL1706 combined with SOX | Xiangdong Cheng | Gastric Cancers, Esophagogastric Junction Cancers | 02/26 | 06/31 | | |
NCT05972460: IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 108 | RoW | IMM2510, IMM2510 Injection | ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Zhejiang Cancer Hospital, Fudan University | Advanced Solid Tumors | 12/23 | 10/24 | | |
NCT05911984: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 27 | RoW | 9MW3811 Injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Solid Tumor | 03/24 | 03/24 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
NCT06610799: Study of IBI363 in Patients With Advanced First-line Gastric Cancer |
|
|
| Not yet recruiting | 1 | 40 | RoW | IBI363 | Xiangdong Cheng | IBI363 + Chemotherapy | 06/25 | 12/26 | | |
BAT-8007-001-CR, NCT05879627: To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 250 | RoW | BAT8007 for injection, Recombinant all human anti Nectin-4 monoclonal antibody for injection Exatecan conjugate | Bio-Thera Solutions, Zhejiang Tumor Hospital | Advanced Solid Tumors | 12/24 | 07/25 | | |
NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies |
|
|
| Terminated | 1 | 13 | RoW | HRS2300, HRS2300、 SHR-1316, HRS2300、SHR-1701, HRS2300、trametinib, HRS2300、Almonertinib | Jiangsu HengRui Medicine Co., Ltd. | Advanced Malignancies | 02/23 | 05/23 | | |
| Recruiting | 1 | 71 | RoW | TQB2103 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Neoplasm | 05/25 | 05/25 | | |
NCT05836948: The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 174 | RoW | SHR-9839 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 05/26 | 06/26 | | |
NCT04657848: Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy |
|
|
| Recruiting | N/A | 100 | RoW | proximal gastrectomy combined with Cheng's Giraffe reconstruction | Zhejiang Cancer Hospital | Gastric Cancer, Reflux Esophagitis | 06/21 | 06/23 | | |
NCT04793672: Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis |
|
|
| Completed | N/A | 4100 | RoW | Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected. | Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Zhejiang Hospital of TCM, Wenzhou Medical University, Fujian Cancer Hospital, RenJi Hospital, Tongde Hospital of Zhejiang, Kecheng District People's Hospital, Yueyang Central Hospital, Shandong Cancer Hospital and Institute, Shanxi Province Cancer Hospital, Liaoning Tumor Hospital & Institute, Harbin Cancer Hospital, Yuhang District People's Hospital, Hainan Cancer Hospital, Zigong Fourth People's Hospital, Henan University of Science and Technology | Malignant Tumor | 04/22 | 12/23 | | |
NCT05385809: A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer |
|
|
| Recruiting | N/A | 100 | RoW | | Zhejiang Cancer Hospital, Innovent Biologics, Inc. | Unresectable Gastric Cancer | 07/22 | 12/23 | | |
NCT05269056: Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics |
|
|
| Recruiting | N/A | 300 | RoW | | Zhejiang Cancer Hospital, Nanjing Geneseeq Technology Inc | Early Gastric Cancer | 11/22 | 05/23 | | |
| Recruiting | N/A | 200000 | RoW | questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT) | Zhejiang Cancer Hospital, Fenghua District People's Hospital, Ningbo City, Fenghua District Traditional Chinese Medicine Hospital, Ningbo City, Xikou Hospital in Fenghua District, Ningbo City, Yongkang Traditional Chinese Medicine Hospital, Yongkang First People's Hospital | Gastrointestinal Tumors | 12/27 | 12/28 | | |
NCT06642857: Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer. |
|
|
| Recruiting | N/A | 150 | RoW | Peripheral blood, tougue coating, saliva, and feces | Xiangdong Cheng | Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | 02/26 | 02/26 | | |
NCT05794841: Multi-omics Study of Tongue Coating in Malignant Tumors of Digestive Tract |
|
|
| Recruiting | N/A | 20000 | RoW | Tongue coating sample collection and multi-omics analysis | Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Liaoning Tumor Hospital & Institute, RenJi Hospital, Fujian Cancer Hospital, Sun Yat-sen University, The Second Affiliated Hospital of Harbin Medical University, Sichuan Cancer Hospital and Research Institute, Zhejiang Provincial Tongde Hospital, Yuhang District Hospital of Traditional Chinese Medicine, The First People's Hospital of Yuhang District, The First Affiliated Hospital of Anhui University of Chinese Medicine, BGI-Shenzhen, Shangyu People's Hospital, Xianju People's Hospital, Shanghai Zhongshan Hospital | Malignant Tumors of Digestive Tract | 03/24 | 03/25 | | |
NCT06614179: A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established |
|
|
| Recruiting | N/A | 100000 | RoW | | Xiangdong Cheng | Abdominal Neoplasm | 12/29 | 12/29 | | |
NCT05991947: Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer |
|
|
| Recruiting | N/A | 1100 | NA | No intervention | Zhejiang Cancer Hospital | Gastric Cancer, Healthy | 12/25 | 12/25 | | |
NCT05617469: DLCS for Predicting Neoadjuvant Chemotherapy Response |
|
|
| Recruiting | N/A | 1100 | RoW | develop and visualized a radio-clinical signatures from pretreatment oversampled CT images | Zhejiang Cancer Hospital | Gastric Cancer, CT Images, Deep Learning, Neoadjuvant Chemotherapy, Tumor Regression Grade | 01/23 | 07/23 | | |
| Yang, Haiyan |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 2 | 26 | RoW | Rituximab, chidamide, lenalidomde | Zhejiang Cancer Hospital | Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 03/22 | 12/22 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT05290090: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL |
|
|
| Recruiting | 2 | 31 | RoW | Rituximab, Lenalidomide, Zanubrutinib and RCHOP, BGB-3111 | Zhejiang Cancer Hospital | Diffuse Large B Cell Lymphoma | 06/24 | 12/25 | | |
NCT06674096: RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL |
|
|
| Recruiting | 2 | 44 | RoW | RLC-CRCHOP | Zhejiang Cancer Hospital | Double-expressor Lymphoma | 12/29 | 06/30 | | |
NCT05992597: ZR2 Sequential Immunochemotherapy for Newly Treated MCL |
|
|
| Recruiting | 2 | 48 | RoW | ZR2 RDHAP | Zhejiang Cancer Hospital | Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma | 08/25 | 12/26 | | |
NCT06086197: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 41 | RoW | Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin | Zhejiang Cancer Hospital | Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | 10/25 | 10/26 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
| Yu, Aijun |
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
|
|
| Recruiting | 3 | 35 | RoW | Mirvetuximab Soravtansine, IMGN853, MIRV | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/23 | 12/23 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
